stockrowNeurocrine Biosciences, Inc.
NBIX Healthcare Drug Manufacturers Specialty & Generic
Neurocrine Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 21.4% from fiscal 2024.
- Revenue
- +41.2%
- EPS
- −3.67%
- Free cash flow
- +79.0%
Quarter to September 2026, against a year earlier
Follow NBIX
Alert me
Neurocrine Biosciences, Inc. (NBIX) Free cash flow margin
Neurocrine Biosciences, Inc.'s free cash flow margin over the twelve months to 30 September 2026 was 28.1%, up 1.9 percentage points from fiscal 2025 (26.2%). Over the past ten years it has ranged from −735.2% (fiscal 2016) to 26.2% (fiscal 2025) — the current reading is the highest in ten years. That is above the Drug Manufacturers Specialty & Generic industry median of 0.00% and above the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | 26.2% | 2.51 |
| FY2024 | 23.7% | 4.50 |
| FY2023 | 19.2% | (2.53) |
| FY2022 | 21.7% | 1.13 |
| FY2021 | 20.6% | (0.25) |
| FY2020 | 20.8% | 4.02 |
| FY2019 | 16.8% | (0.19) |
| FY2018 | 17.0% | 79.63 |
| FY2017 | −62.7% | 672.52 |
| FY2016 | −735.2% | (533.23) |
Against its own ten years
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| NBIX Neurocrine Biosciences, Inc. | 28.1% |
| UTHR United Therapeutics Corporation compare | 27.2% |
| ZTS Zoetis Inc. compare | 24.4% |
| KNSA Kiniksa Pharmaceuticals International, plc compare | 20.9% |
| VTRS Viatris Inc. compare | 16.3% |
| ALKS Alkermes plc compare | 13.0% |
| ELAN Elanco Animal Health Incorporated compare | 7.55% |
| RDY Dr. Reddy's Laboratories Ltd compare | 2.88% |
| HLN Haleon PLC Sponsored ADR compare | 0.00% |
| Drug Manufacturers Specialty & Generic industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on NBIX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement